{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T10:48:30Z","timestamp":1785754110475,"version":"3.56.0"},"reference-count":81,"publisher":"Informa UK Limited","issue":"8","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2026,8,3]]},"DOI":"10.1080\/14737140.2026.2628071","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T13:24:46Z","timestamp":1770643486000},"page":"1003-1017","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Immune checkpoint inhibitors in urothelial carcinoma: a practical framework for patient selection, toxicity management, response assessment, and treatment sequencing"],"prefix":"10.1080","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8856-549X","authenticated-orcid":false,"given":"Abdul Rahman","family":"Al Armashi","sequence":"first","affiliation":[{"name":"University Hospitals Case Comprehensive Cancer Center, Case Western Reserve University","place":["Cleveland, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Gong","sequence":"additional","affiliation":[{"name":"University Hospitals Case Comprehensive Cancer Center, Case Western Reserve University","place":["Cleveland, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Barata","sequence":"additional","affiliation":[{"name":"University Hospitals Case Comprehensive Cancer Center, Case Western Reserve University","place":["Cleveland, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6225-7555","authenticated-orcid":false,"given":"Jason","family":"Brown","sequence":"additional","affiliation":[{"name":"University Hospitals Case Comprehensive Cancer Center, Case Western Reserve University","place":["Cleveland, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Garcia","sequence":"additional","affiliation":[{"name":"University Hospitals Case Comprehensive Cancer Center, Case Western Reserve University","place":["Cleveland, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Sheng","sequence":"additional","affiliation":[{"name":"University Hospitals Case Comprehensive Cancer Center, Case Western Reserve University","place":["Cleveland, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.11.014"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117"},{"key":"e_1_3_5_7_1","unstructured":"United Nations Department of Economic and Social Affairs Population Division. World population prospects 2022: summary of results. 2022."},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"e_1_3_5_9_1","unstructured":"European Association of Urology (EAU). Guidelines panel. Muscle-invasive and metastatic bladder cancer [Internet]. [cited 2025 Oct 10]. Available from: https:\/\/uroweb.org\/guidelines\/muscle-invasive-and-metastatic-bladder-cancer"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034442"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00473-5"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.11.2228"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2024.152267"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.016"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000147"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2020.100042"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu210"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.7326\/M17-2073"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.625872"},{"issue":"1","key":"e_1_3_5_20_1","first-page":"e81","article-title":"Variant histology in bladder cancer patients with advanced\/metastatic disease: impact on clinical outcomes in first-line immunotherapy or chemotherapy","volume":"20","author":"Maiorano BA","year":"2022","unstructured":"Maiorano BA, Nardelli A, Lucarelli A, et al. Variant histology in bladder cancer patients with advanced\/metastatic disease: impact on clinical outcomes in first-line immunotherapy or chemotherapy. Clin Genitourin Cancer. 2022;20(1):e81\u2013e88.","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"e_1_3_5_21_1","first-page":"680","article-title":"Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies","volume":"77","author":"Necchi A","year":"2020","unstructured":"Necchi A, Raggi D, Gallina A, et al. Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies. Eur Urol. 2020;77(5):680\u2013683.","journal-title":"Eur Urol"},{"issue":"5","key":"e_1_3_5_22_1","first-page":"732","article-title":"Impact of variant histology on outcomes in patients with advanced urothelial carcinoma treated with pembrolizumab: post hoc analysis of KEYNOTE-045 and KEYNOTE-361","volume":"211","author":"Grivas P","year":"2024","unstructured":"Grivas P, Bismar TA, Alva AS, et al. Impact of variant histology on outcomes in patients with advanced urothelial carcinoma treated with pembrolizumab: post hoc analysis of KEYNOTE-045 and KEYNOTE-361. J Urol. 2024;211(5):732\u2013742.","journal-title":"J Urol"},{"issue":"6","key":"e_1_3_5_23_1","first-page":"673","article-title":"Multiparametric radiomics and artificial intelligence panels to predict complete response to neoadjuvant pembrolizumab in muscle-invasive bladder cancer: PURE-01 study biomarkers","volume":"2","author":"Necchi A","year":"2019","unstructured":"Necchi A, Bandini M, Calareso G, et al. Multiparametric radiomics and artificial intelligence panels to predict complete response to neoadjuvant pembrolizumab in muscle-invasive bladder cancer: PURE-01 study biomarkers. Eur Urol Oncol. 2019;2(6):673\u2013683.","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"e_1_3_5_24_1","first-page":"62","article-title":"Urothelial cancer with neuroendocrine features: survival after radical cystectomy","volume":"204","author":"Wang Y","year":"2020","unstructured":"Wang Y, Thomas A, Lau C, et al. Urothelial cancer with neuroendocrine features: survival after radical cystectomy. J Urol. 2020;204(1):62\u201368.","journal-title":"J Urol"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1277"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006398"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00032"},{"key":"e_1_3_5_29_1","unstructured":"CDC. Shingles Vaccine Recommendations [Internet]. Shingles (Herpes Zoster). 2024 [cited 2025 Oct 10]. Available from: https:\/\/www.cdc.gov\/shingles\/hcp\/vaccine-considerations\/index.html"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad164"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0726"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2020200443"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-018-2264-0"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.1136"},{"issue":"24","key":"e_1_3_5_36_1","first-page":"2301","article-title":"ctDNA-guided adjuvant atezolizumab in urothelial carcinoma","volume":"391","author":"Powles T","year":"2024","unstructured":"Powles T, Assaf ZJ, Davarpanah N, et al. ctDNA-guided adjuvant atezolizumab in urothelial carcinoma. N Engl J Med. 2024;391(24):2301\u20132312.","journal-title":"N Engl J Med"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001372"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1860"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33980-9"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1109\/OJEMB.2022.3163533"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4574"},{"key":"e_1_3_5_44_1","unstructured":"Food and Drug Administration (FDA). FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma Internet]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-erdafitinib-locally-advanced-or-metastatic-urothelial-carcinoma"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308849"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02005"},{"key":"e_1_3_5_47_1","unstructured":"Food and Drug Administration (FDA). Withdrawn: cancer accelerated approvals [Internet]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/withdrawn-cancer-accelerated-approvals"},{"key":"e_1_3_5_48_1","unstructured":"Gilead provides update on phase 3 TROPiCS 04 study [Internet]. [cited 2025 Oct 25]. Available from: https:\/\/www.gilead.com\/news\/news-details\/2024\/gilead-provides-update-on-phase-3-tropics-04-study"},{"key":"e_1_3_5_49_1","unstructured":"Gilead Sciences. Gilead sciences to withdraw sacituzumab govitecan bladder cancer approval status [Internet]. CancerNetwork. 2024 [cited 2025 Oct 25]. Available from: https:\/\/www.cancernetwork.com\/view\/gilead-sciences-to-withdraw-sacituzumab-govitecan-bladder-cancer-approval-status"},{"key":"e_1_3_5_50_1","unstructured":"Accelerated Approval for Bladder Cancer Drug to Be Withdrawn After Negative Trial [Internet]. [cited 2025 Oct 25]. Available from: https:\/\/ascopost.com\/news\/october-2024\/accelerated-approval-for-bladder-cancer-drug-to-be-withdrawn-after-negative-trial\/"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21788"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.9265"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.18085"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.21037\/tau-2025-45"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-023-00640-5"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34848"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.2671"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.12.002"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.25810"},{"key":"e_1_3_5_60_1","unstructured":"Centers for Medicare & Medicaid Services (CMS). Enhancing Oncology model [Internet]. [cited 2025 Oct 28]. Available from: https:\/\/www.cms.gov\/priorities\/innovation\/innovation-models\/enhancing-oncology-model"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21443"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70696"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2023.05.006"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-020-06847-0"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/1754-9485.13426"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb5920"},{"key":"e_1_3_5_67_1","unstructured":"Weinfurt KP. Why are we talking about pragmatic trials? [Internet]. Rethinking clinical trials. 2025 [cited 2025 Oct 25]. Available from: https:\/\/rethinkingclinicaltrials.org\/chapters\/design\/what-is-a-pragmatic-clinical-trial\/what-is-a-pragmatic-clinical-trialv2\/"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf3363"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009358"},{"key":"e_1_3_5_70_1","unstructured":"UroToday. Phase II trial compares tobemstomig alone or with tiragolumab vs atezolizumab in untreated metastatic urothelial cancer [Internet]. ESMO. 2023. Available from: https:\/\/www.urotoday.com\/conference-highlights\/esmo-2023\/esmo-2023-bladder-cancer\/147532-esmo-2023-phase-ii-trial-compares-tobemstomig-alone-or-with-tiragolumab-vs-atezolizumab-in-untreated-metastatic-urothelial-cancer.html"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1583116"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06734-2"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2023.02.019"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-10-37"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13918"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.669150"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.4598ascopubs\/"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00671-0"},{"key":"e_1_3_5_79_1","unstructured":"ClinicalTrials.gov [Internet]. [cited 2025 Oct 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05394337"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2322562"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.241877"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32090484"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.104967"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2026.2628071","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14737140.2026.2628071","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2026.2628071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T10:23:47Z","timestamp":1785752627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2026.2628071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":81,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,3]]}},"alternative-id":["10.1080\/14737140.2026.2628071"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2026.2628071","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-11-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}